In conclusion, these data demonstrate that LAPTM5 mediates the sensitivity to temozolomide by the inhibition of CD40-induced NFκB pathway activation in CD40-positive glioblastoma cells. The gene discussed is LAPTM5; the disease is glioblastoma.